



# Latest Canadian Consensus Conference on the Diagnosis and Treatment of Dementia: What's in It for Primary Care?

www.cambridge.org/cjg

Laura Rojas-Rozo<sup>1</sup> , Linda Lee<sup>2</sup> , Vladimir Khanassov<sup>1</sup>, Saskia Sivananthan<sup>3</sup>, Zahinoor Ismail<sup>4</sup>, Serge Gauthier<sup>5</sup> and Isabelle Vedel<sup>1,6</sup>

## Article

**Cite this article:** Rojas-Rozo, L., Lee, L., Khanassov, V., Sivananthan, S., Ismail, Z., Gauthier, S., & Vedel, I. (2024). Latest Canadian Consensus Conference on the Diagnosis and Treatment of Dementia: What's in It for Primary Care? *Canadian Journal on Aging / La Revue canadienne du vieillissement* 43(2), 185–196.  
<https://doi.org/10.1017/S0714980823000521>

Received: 02 November 2021  
Accepted: 13 June 2023

**Mots-clés:**  
vieillesse; démence; troubles neurocognitifs; dépistage; traitement neuroimagerie; interventions non pharmacologiques

**Keywords:**  
aging; dementia; risk reduction; screening; treatment; neuroimaging; non-pharmacological interventions

**Corresponding author:**  
La correspondance et les demandes de tirés-à-part doivent être adressées à : /  
Correspondence and requests for offprints should be sent to: Laura Rojas-Rozo, Department of Family Medicine, McGill University, 5858 Chemin de la Côte-des-Neiges, 3rd Floor, Montreal, QC H3S 1Z1 (laura.rojasrozo@mail.mcgill.ca).

<sup>1</sup>Department of Family Medicine, McGill University, Montreal, QC, Canada, <sup>2</sup>Department of Family Medicine, McMaster University, Hamilton, ON, Canada, <sup>3</sup>Alzheimer Society of Canada, Toronto, ON, Canada, <sup>4</sup>Departments of Psychiatry, Clinical Neurosciences, and Community Health Sciences, University of Calgary, Calgary, AB, Canada, <sup>5</sup>Departments of Neurology and Neurosurgery, and Psychiatry, McGill University, Montreal, QC, Canada and <sup>6</sup>Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada

## Résumé

En 2020, la cinquième Conférence canadienne consensuelle sur le diagnostic et le traitement de la démence (CCCDTD5) a publié des recommandations mises à jour pour la prise en charge clinique des personnes vivant avec un trouble neurocognitif et de leurs proches aidants. Lors des réunions de la CCCDTD5, une liste de recommandations pour les soins liés à la démence a été compilée. Avec l'aide de médecins de famille et du Consortium canadien sur la neurodégénérescence associée au vieillissement, nous avons sélectionné les recommandations les plus pertinentes de la CCCDTD5 pour les soins primaires, et les avons adaptées et résumées dans le présent manuscrit dans le but d'en faciliter la consultation et l'utilisation. Ces recommandations portent sur a) la réduction des risques, b) le dépistage et le diagnostic, c) la déprescription des médicaments pour les troubles neurocognitifs, et d) les interventions non pharmacologiques. L'élaboration de recommandations pour la prise en charge des troubles neurocognitifs est un processus itératif qui évolue au fur et à mesure que sont publiées de nouvelles preuves sur les interventions dans ce domaine. Ces recommandations sont importantes dans le contexte des soins primaires, qui constituent le point d'entrée des personnes vivant avec la démence dans le réseau de la santé.

## Abstract

In 2020, the fifth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD5) published up-to-date recommendations for the clinical management of persons living with dementia (PLWD) and their caregivers. During the CCCDTD5 meetings, a list of recommendations for dementia care was compiled. With the aid of family physicians and the Canadian Consortium on Neurodegeneration in Aging, we selected the most relevant CCCDTD5 recommendations for primary care and tailored and summarized them in the present manuscript to facilitate their reference and use. These recommendations focus on (a) risk reduction, (b) screening and diagnosis, (c) deprescription of dementia medications, and (d) non-pharmacological interventions. The development of recommendations for the ongoing management of dementia is an iterative process as new evidence on interventions for dementia is published. These recommendations are important in the primary care setting as the entry point for PLWD into the health system.

## Introduction

Dementia affects more than 50 million people around the world (Alzheimer Disease International, 2020), and it is characterized by a progressive decline in cognition (American Psychiatric Association, 2013; World Health Organization, 2012), particularly affecting people 65 years and older. The symptomatology associated with dementia and its progression can vary, depending on the severity of the disease and from person to person. Dementia can affect almost all activities of daily living and the ability to manage personal finances (Hsu & Willis, 2013), transportation (Carr & Ott, 2010), and socializing over time (Honda, Meguro, Meguro, & Akanuma, 2013). An aging population with an increasing prevalence of dementia has created the need for primary care clinicians to take on a more essential and active role in dementia care in collaboration with specialists and community agencies (Hogan et al., 2012).

In 2019, the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD) met for the fifth time (Ismail et al., 2020). Since 1989, this conference has provided

© Canadian Association on Gerontology 2023. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.



updated recommendations to guide Canadian health care professionals, including primary care practitioners, in the management of persons living with dementia (PLWD) and their caregivers. The Canadian health care system infrastructure places primary care as the main entry for health care services. Thus, primary care providers oversee the detection, diagnosis, and treatment of dementia. Furthermore, the previous CCCDTD statements and the 2019 Canadian Academy of Health Sciences recommended that the diagnosis and management of patients with dementia should mainly be the responsibility of primary health care (Canadian Academy of Health Science, 2019; CCCDTD3, 2007).

In Canada, according to the 2015 Commonwealth Fund Survey of Family Physicians, more than 86 per cent of family physicians “often” or “sometimes” provided medical care for PLWD (Canadian Institute for Health Information, 2022; The Common Wealth Fund, 2015). We know that primary care providers are motivated to provide care for PLWD (Arsenault-Lapierre *et al.*, 2021). However, it is well known that some family physicians and primary care providers have difficulties getting involved with the dementia population due to multiple factors, such as time constraints (Arsenault-Lapierre *et al.*, 2021) and stigma (Bacsu, Mateen, Johnson, Viger, & Hackett, 2020), and requiring more support and training (Arsenault-Lapierre *et al.*, 2021). As a result, family physicians, despite the availability of guidelines for the treatment of dementia, continue to feel unequipped for providing adequate care for PLWD (Bacsu *et al.*, 2020). Physicians often indicate that guidelines are typically lengthy and complex to read (Gupta *et al.*, 2016). The issues mentioned above not only affect family physicians and primary care providers in their practices, but also PLWD and their care partners still perceive that their needs are unmet when receiving care in primary care settings. It is thus essential to present the latest recommendations from the fifth CCCDTD (CCCTDT5) in a format that is relevant and usable to Canadian primary care practitioners (Black *et al.*, 2013; Khanassov, Rojas-Rozo, Sourial, Yang, & Vedel, 2021).

To continue to provide relevant and up-to-date information for all professionals involved in the care of PLWD, the CCCDTD5 made recommendations regarding diagnosis and management, including dementia case finding and detection, use of neuroimaging in dementia diagnoses, risk reduction and prevention of dementia, and medication use. Furthermore, for the first time during these conferences, a working group was formed to specifically address psychosocial and non-pharmacological interventions for PLWD and their caregivers (Ismail *et al.*, 2020). However, these guidelines are extensive, with more than 30 pages of recommendations for the treatment and management of dementia. As a result, in the present article, we selected and tailored recommendations that are relevant for the practice of family practitioners and interdisciplinary primary care teams (that could include several health care professionals such as social workers, nurse practitioners, and psychologists).

## Methodology

As explained in detail elsewhere (Ismail *et al.*, 2020), the methodology used during the CCCDTD5 was based on the Appraisal of Guidelines for Research and Evaluation (AGREE) II collaboration (Brouwers *et al.*, 2010). Recommendations were rated using the Grade of Recommendations, Assessment, Development, and Evaluations (GRADE) framework. A recommendation was accepted if it was approved by 80 per cent or more of the participants from the panel of experts (Ismail *et al.*, 2020).

The CCCDTD5's lead members recommended knowledge translation efforts for tailoring the recommendations for primary care. With the aid of family physicians who were part of the conference and/or of the Canadian Consortium on Neurodegeneration in Aging (CCNA), the most relevant recommendations for primary care and family physicians were selected. With the aim of making these recommendations more practical and easier to consult, we tailored and summarized the recommendations most relevant for family practitioners and interdisciplinary primary care teams (see Figure 1 for a summary and Table 1 for the detailed recommendations with their respective GRADE classifications as well as the approval percentage from the panel of experts). As part of our knowledge translation strategy, we also created tables accompanying the different recommendations, as well as visual representations to help better understand where in the dementia journey they may be applied.

Recommendations more relevant to other specialists and research endeavours were not selected for this article as they did not prove as useful for primary care, for instance, specific imaging guidelines and definitions more suited to specialists. The complete list of recommendations is published elsewhere, with specific information on the evidence for each recommendation as well as the consensus percentage approval (Gauthier *et al.*, 2020; Ismail *et al.*, 2020; Vedel *et al.*, 2020).

In the text below, we summarize recommendation key points and offer practical guidance on how to implement them. After the recommendations, we provide a list of public resources to support primary care providers in their practices and to support their patients, as well as two infographics depicting the dementia journey for both health and social care providers (Figure 2) and PLWD (Figure 3), developed in collaboration with the Alzheimer Society of Canada.

## CCCTDT5 Recommendations Relevant for Primary Care Clinicians

### Risk reduction for dementia: Recommendations for all patients

**Nutrition.** To decrease the risk of cognitive decline, it is recommended that persons adhere to a Mediterranean diet, increase their fruit and vegetable intake, and consume a high level of monounsaturated and polyunsaturated fatty acids (e.g., walnuts, flaxseeds), as well as consume a low level of saturated fatty acids (e.g., beef, cream, butter).

**Physical exercise.** Physical exercise is recommended for reducing the risk of cognitive decline. Experts currently recommend no specific exercises, and the recommendation should be tailored for each case. Exercise of at least moderate intensity should be recommended for older adults, such as brisk walking. In this type of exercise, the patient should still be able to talk. Family practitioners can recommend aerobic exercise (e.g., swimming, walking), resistance training (e.g., deadlifts, working with all major groups – legs, hips, back abdomen), dance, and mind-body exercise (e.g., Tai Chi, Qigong).

**Social engagement and education.** It is recommended that attention be given to social circumstances and supports across the life course, including poverty reduction strategies and opportunities for social engagement (e.g., meeting friends and family in person, talking on the phone), as well as support for educational attainment (e.g., access to education) and ongoing educational experiences.




Figure 1. CCCD5 recommendations most relevant for primary care clinicians.

**Medications.** Older people should have a multidimensional health assessment, including medication use. Family practitioners should aim to minimize patients' exposure to medications known to have highly anticholinergic properties and replace these with other medications when necessary and feasible. See Table 2 for a list of medications with anticholinergic properties to be avoided based on the American Geriatrics Society Beers Criteria for potentially inappropriate medication use in older adults (The American Geriatrics Society Beers Criteria Update Expert Panel, 2019).

#### Risk reduction for dementia: Recommendations for patients at risk of dementia

**Hearing.** It is recommended that persons who are at risk of dementia (see Table 1), as well as their caregivers be asked whether they have any difficulty hearing in their everyday life (rather than asking whether they are experiencing hearing loss). If symptoms of hearing loss are reported, then hearing loss should be confirmed by audiometry conducted by an audiologist meeting provincial regulations for the practice of audiology. If confirmed, audiological rehabilitation and/or hearing aids or other devices should be considered.

All persons at risk of dementia (see Table 3) should have an audiological and/or otoscopic examination and review of medications for potential ototoxicity. If the patient has chronic otitis or fails the otoscopy, that patient should have a referral to otolaryngology.

**Sleep.** A careful sleep history, including assessment of sleep time and symptoms of sleep apnea, should be included in the assessment of any patient at risk for dementia (see Table 3). Patients for whom sleep apnea is suspected should be referred for polysomnography and/or a sleep specialist consultation for consideration of treatment with a CPAP machine. It is recommended that persons avoid severe sleep deprivation (< 5 hours) and aim to have 7 to 8 hours of sleep per night.

**Cognitive training and stimulation.** It is recommended that persons at risk increase or maintain engagement in cognitively stimulating activities such as volunteering, long-life learning, and other cognitively stimulating pastimes. When accessible, empirically supported individual computer-based and group cognitive training may be proposed for people at risk and those with mild cognitive

impairment (MCI) or dementia. However, further studies are needed; no specific program can be endorsed at this time.

#### Screening and diagnosis

**Screening for people at risk of dementia or with symptoms suggestive of cognitive decline.** Cognitive testing is not recommended for screening asymptomatic adults for the presence of MCI or dementia, even in the presence of risk factors. However, if persons are at elevated risk for cognitive disorders (see Table 3), it is reasonable to ask the person and an informant (e.g., caregiver, spouse, child, relative, close friend) about concerns regarding memory and, if present, to evaluate using validated cognitive screening tools (see Table 4). As well, given the underrecognition of dementia in the community, clinicians should be aware of signs and symptoms suggestive of cognitive decline (see Table 5), particularly if reported by family or friends. If signs or symptoms are present, clinicians should consider evaluating them with cognitive screening tools. In the context of the current coronavirus disease (COVID-19) pandemic, recommendations have also been made elsewhere regarding the use of virtual cognitive testing (Geddes et al., 2020).

**Diagnosis and use of cognitive tests.** Screening tools are used to increase the pre-test probability of diagnosis; they alone should not be used to make the diagnosis. The diagnosis requires clinical interviews with the individual and corroborated history with the caregiver, if available, a focused physical examination, and consideration of cognitive test results, which usually require more comprehensive cognitive test tools (Molnar, Benjamin, Hawkins, Briscoe, & Ehsan, 2020). Brief assessment screening tools can be easily administered in family practice. However, for diagnostic purposes, when time permits, more comprehensive tools should be considered. These are listed in Table 4. The diagnosis of MCI or dementia should not be solely based on the results of cognitive screening tests; assessment of functional abilities is important.

**Subjective cognitive decline.** Subjective cognitive decline (SCD) is a condition in which persons complain about worsening of cognition, but both their function and performance on objective cognitive testing are within normal limits (Stuart & Nitrini, 2016).

**Table 1.** The most relevant CCCDTD 5 recommendations for primary care clinicians with GRADE classification and approval percentage by the panel of experts

CCCDTD5 Recommendations for Primary Care Clinicians	GRADE	Consensus Approval
<b>Category: Risk Reduction for Dementia</b>		
We recommend adherence to a Mediterranean diet to decrease the risk of cognitive decline.	1B	91%
We recommend increasing fruit and vegetable intake.	1B	88%
We recommend a high level of consumption of monounsaturated and polyunsaturated fatty acids and a low consumption of saturated fatty acids, to reduce the risk of cognitive decline.	1B	92%
We recommend physical activity interventions of at least moderate intensity to improve cognitive outcomes among older adults.	1B	96%
We recommend physical activity interventions involving aerobic exercise to improve cognitive outcomes among people with mild cognitive impairment (MCI).	2B	94%
There is promising evidence that dance interventions and mind-body exercise (for example, Tai Chi, Qigong) of moderate dose improve cognitive outcomes among older adults but results from larger, high quality trials are needed.	2B	84%
We recommend attention to social circumstances and supports across the life course, including poverty reduction strategies and opportunities for social engagement.	1B	90%
We recommend support for educational attainment, particularly in early life <sup>+</sup> , but also for ongoing educational experiences in mid and later life*.	1B <sup>+</sup> , 1C*	98%
Multidimensional health assessment for older adults, including of medication use, with the aim of identifying reversible or modifiable health conditions and rationalizing medication use.	1B	92%
Exposure to medications known to exhibit highly anticholinergic properties should be minimized in older persons. Alternative medications should be used for specific indications where medications with anticholinergic properties are indicated (e.g., depression, neuropathic pain, urge type urinary incontinence).	1B	100%
Persons with cognitive complaints, MCI, or dementia (and their care partner, if there is one) should be questioned about symptoms of hearing loss to improve cognitive outcomes and risk reduction. It is recommended that persons are asked whether they have any difficulty hearing in their everyday life (rather than asking whether they have a hearing loss).	1B	93%
We recommend following the WHO (2019) guidelines for risk reduction of cognitive decline and dementia including: (a) audiological examination and/or otoscopic examination; (b) the review of medications for potential ototoxicity; (c) referral to otolaryngology for persons with chronic otitis media or who fail otoscopy.	1A	93%
A careful sleep history, including assessment of sleep time and symptoms of sleep apnea, should be included in the assessment of any patient at risk for dementia. Patients in whom sleep apnea is suspected should be referred for polysomnography and/or sleep specialist consultation for consideration of treatment.	1C	96%
Adults with sleep apnea should be treated with Continuous Positive Airway Pressure (CPAP), which may improve cognition and decrease the risk of dementia.	1C	96%
Avoiding severe (< 5 h) sleep deprivation, and targeting 7-8 hours of sleep per night, may improve cognition and decrease the risk of dementia.	1C	94%
We recommend that accessible empirically supported individual computer-based and group cognitive training be proposed to people at risk and those with a diagnosis of mild cognitive impairment or mild dementia. We recommend additional studies to optimize effective delivery of training, and evaluation of their cost effectiveness. No specific program can be endorsed at this time.	1B	83%
We recommend that individuals be advised to increase or maintain their engagement in cognitively stimulating activities such as cognitively stimulating pastimes, volunteering, and long-life learning. No particular activities can be suggested at this time, but data suggest that engaging in a variety of cognitively stimulating activities is preferable.	1C	96%
<b>Category: Screen and Diagnosis for Dementia</b>		
Due to variability in insight into cognitive, functional, and behavioral changes, report from a reliable informant is an essential component for the assessment of patients with suspected neurocognitive disorders at all settings.	1C	91%
Cognitive testing to screen asymptomatic adults for the presence of mild cognitive impairment or dementia, including asymptomatic persons with risk factors such as family history or vascular risk factors, is not recommended.	1C	95%
Routine screening of asymptomatic individuals has no evidence at this point. Cognitive testing to screen asymptomatic adults for the presence of mild cognitive impairment or dementia is not recommended.	1C	95%
Primary care health professionals should be vigilant for potential symptoms of cognitive disorders in older or at-risk individuals, including but not limited to: reported cognitive symptoms by the patient or an informant, otherwise unexplained decline in instrumental activities of living, missed appointments or difficulty remembering or following instructions or taking medications, decrease in self care, victimized by financial scams, or new onset later-life behavioral changes including new depression or anxiety. <sup>+</sup> If there is a clinical concern for a cognitive disorder (which may not always be shared by the patient due to anosognosia), then validated assessments of cognition, activities of daily living, and neuropsychiatric symptoms are indicated (see subsequent sections for suggestions for valid tools).*	(1C), <sup>+</sup> 1A*	95%

(Continued)



Table 1. Continued

CCCDT5 Recommendations for Primary Care Clinicians	GRADE	Consensus Approval
In persons with elevated risk for cognitive disorders or with medical conditions associated with cognitive disorders – (a) a history of stroke or transient ischemic attack (TIA); (b) late-onset depressive disorder or a lifetime history of major depressive disorder; (c) untreated sleep apnea; (d) unstable metabolic or cardiovascular morbidity; (e) a recent episode of delirium; (f) first major psychiatric episode at an advanced age (psychosis, anxiety, depression, mania); (g) recent head injury; (h) Parkinson's disease – it is reasonable to ask the patient and an informant about concerns regarding cognition and behavior. <sup>†</sup> If clinically significant cognitive concerns are elicited, then further evaluation using validated assessments of cognition, behaviour, and function is appropriate (see subsequent sections for suggestions for valid tools).*	2C, <sup>†</sup> 1B*	98%
Primary care health professionals should stay vigilant for potential early symptoms of cognitive disorders in older individuals who may be less likely to report due to their lack of insight, social isolation, or sociocultural beliefs, and in older individuals with warning signs, including but not limited to: reported cognitive symptoms by the patient or an informant, otherwise unexplained decline in instrumental activities of living, missed appointments, showing up to appointments at the incorrect time or day, difficulty remembering or following instructions or taking medications, decrease in self-care, or new onset of later-life behavioural changes including new depression or anxiety. <sup>†</sup> If there is a clinical concern for a cognitive disorder (which may not always be shared by the patient due to their lack of insight), then validated assessments of cognition, activities of daily living, and neuropsychiatric symptoms are indicated (see subsequent sections for suggestions for valid tools).*	1C, <sup>†</sup> 1A*	95%
The distinction between MCI and AD is important and is currently made on the basis of clinical assessment of cognition and function. For screening purposes, examining the complaint with the patient and a family member, and proceeding with an objective assessment of cognition and functional impairment should be done.	1A	88%
An objective assessment of the patient's cognitive function could be achieved by using rapid psychometric screening tools such as the Memory Impairment Screen (MIS)+ clock drawing test (CDT), the Mini-Cog, the AD8, the 4-item version of the MoCA (Clock-drawing, Tap-at-letter-A, Orientation, and Delayed-recall), and the GP Assessment of Cognition (GPCOG).	2B	93%
If more time is allowed, preference should be given to using a more comprehensive psychometric screening tool (the Modified Mini-Mental State (3MS) examination, the Mini-Mental State Examination (MMSE), or the Rowland Universal dementia assessment scale (RUDAS). MMSE remains the most widely used instrument, with high sensitivity and specificity for separating moderate dementia from normal cognition and is recommended in many countries. However, it lacks sensitivity for the diagnosis of mild dementia or MCI. The MoCA is more sensitive to MCI than the MMSE, and its use is recommended when mild cognitive impairment is suspected or in cases where there is suspicion of cognitive impairment or concern about the patient's cognitive status, and the MMSE score is in the "normal" range (24+ out of 30).	1B	93%
Patients presenting with consistent subjective cognitive complaints, with normal cognitive testing, in the absence of any obvious impairment in Instrumental Activities of Daily Living should undergo an appropriate diagnostic workup (i.e., standard dementia medical workup to identify reversible causes and psychiatric symptom assessment, with a special emphasis on depressive and anxious symptoms).	1B	93%
Use of structured scales for: objective cognition (e.g., MoCA, Clock Drawing Test); subjective cognition (e.g., SCD-Q Part 1 [MyCog]); informant reported cognition/function (e.g., ECog, Informant Questionnaire on Cognitive Decline in the Elderly [IQCODE], Lawton Instrumental Activities of Daily Living Scale, Perceived Deficits Questionnaire [PDQ], SCD-Q Part 2 [TheirCog]); and behaviour (e.g., informant report [MBI-C, NPI-Q] and self [GDS, PHQ9, GAD7]) are recommended.	1B	95%
For patients with a negative corroborative history, reassurance should be provided and follow-up offered, if the patient or informant sources note deterioration in the future in any of the domains of cognition, function, and behaviour.	2C	89%
For patients with a positive corroborative history, annual follow-ups are recommended.	1B	91%
For patients with a positive corroborative history, referral to a primary or specialty care memory clinic, and further investigation with laboratory testing, neuroimaging, and detailed neuropsychiatric testing might be considered.	2C	86%
All patients presenting with SCD should be provided with information on the WHO recommendations for the prevention of dementia.	1C	98%
Even in older subjects, anatomical neuroimaging is recommended in most situations, using the following list of indications: onset of cognitive signs/symptoms within the past 2 years, regardless of the rate of progression, unexpected and unexplained decline in cognition and/or functional status in a patient already known to have dementia, recent and significant head trauma, unexplained neurological manifestations (new onset of severe headache, seizures, etc.) at onset or evolution (including gait disturbances), history of cancer, in particular if at risk for brain metastasis, risk of intracranial bleeding, symptoms compatible with NPH, significant vascular factors.	1C	76%; 93%
MRI is recommended over CT, especially given its higher sensitivity to vascular lesions as well as for some subtypes of dementia and rarer conditions.	2C	87%
If available, and in the absence of contraindications, 3T MRI should be favoured over 1.5T.	2C	91%

(Continued)

Table 1. *Continued*

CCCDT5 Recommendations for Primary Care Clinicians	GRADE	Consensus Approval
<b>Category: Deprescribing Medications in Dementia</b>		
The use of aspirin is not recommended for patients with MCI or dementia who have brain imaging evidence of covert white matter lesions of presumed vascular origin without a history of stroke or brain infarcts.	2C	96%
The effects of aspirin on cognitive decline in patients with MCI or dementia who have covert brain infarcts detected on neuroimaging without history of stroke have not been defined; the use of aspirin in this setting is reasonable, but the benefit is unclear.	2C	86%
Cholinesterase inhibitors (ChEIs) (donepezil, galantamine, rivastigmine) and the N-methyl-D-aspartate (NMDA) receptor antagonist memantine may be considered for the treatment of vascular cognitive impairment in individual patients.	2B	89%
For individuals prescribed ChEI for indications other than Alzheimer's disease, Parkinson's disease dementia, dementia of Lewy body, or vascular dementia (e.g., frontotemporal dementia, other neurodegenerative conditions), ChEIs should be discontinued.	1B	93%
Deprescribing of ChEIs or memantine should occur gradually and treatment reinitiated if the individual shows clinically meaningful worsening of cognition, functioning, neuropsychiatric symptoms, or global assessment that appears to be related to cessation of therapy.	1B	98%
Individuals who have had a clinically meaningful reduction in neuropsychiatric symptoms (e.g., psychosis) with cognitive enhancers should continue to be treated with the cognitive enhancer even if there is evidence of cognitive and functional decline.	2B	96%
Decisions related to the deprescribing of cognitive enhancers should take into consideration the patient's preferences (for individuals who can make treatment decisions), their prior expressed wishes (if these are known), and in collaboration with family or substitute decision makers for individuals who are incapable of providing informed consent.	1C	98%
<b>Psychosocial and Non-pharmacological Recommendations for Dementia</b>		
We recommend exercise (group or individual physical exercise) for people living with dementia. We cannot recommend any specific exercise duration or intensity at this time.	1B	93%
Group cognitive stimulation therapy is an intervention for people with dementia, which offers a range of enjoyable activities providing general stimulation for thinking, concentration, and memory usually in a social setting, such as a small group. We recommend considering group cognitive stimulation therapy for people living with mild to moderate dementia.	2B	96%
Psychoeducational interventions for caregivers aim at the development of problem-focused coping strategies, whereas psychosocial interventions address the development of emotion-focused coping strategies. These can include education, counselling, information regarding services, enhancing carer skills to provide care, problem solving, and strategy development. We recommend considering psychosocial and psychoeducational interventions for caregivers of people living with dementia.	2C	96%
Case management is defined as the introduction, modification, or removal of strategies to improve the coordination and continuity of delivery of services, which include the social aspects of care. We recommend considering the use of case management for people living with dementia.	2C	91%
Dementia-friendly organizations/communities are defined as the practice and organization of care/communities that are aware of the impact dementia has on a person's ability to engage with services and manage their health. It promotes the inclusion of people living with dementia and their caregiver in decisions and discussions with the aim of improving outcomes for the persons living with dementia and their caregivers. We recommend considering the development of dementia-friendly organizations/communities for people living with dementia.	2C	91%

Recommendations of the 5th Canadian Consensus Conferences on the Diagnosis and Treatment of Dementia (adapted from Ismail Z, et al.); Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia. *Alzheimer's & Dementia*. 2020;16(8):1182–1189.

\*MMSE remains the most widely used instrument, with high sensitivity and specificity for separating moderate dementia from normal cognition and is recommended in many countries.

+The MoCA is more sensitive to MCI than the MMSE, and its use is recommended when mild cognitive impairment is suspected or in cases where there is suspicion of cognitive impairment or concern about the patient's cognitive status, and the MMSE score is in the "normal" range (24+ out of 30).

Persons presenting with consistent subjective cognitive complaints, with normal cognitive testing, and absence of any obvious impairment in Instrumental Activities of Daily Living should undergo an appropriate diagnostic workup (i.e., standard dementia medical workup to identify reversible causes, as well as psychiatric assessment – with a particular emphasis on depressive and anxious symptoms).

It is recommended to use structure scales for the evaluation of objective cognition, subjective cognition (such as the SCD-Q Part 1), the informant reported cognition (IQCODE, Lawton Instrumental

Activities of Daily Living Scale, PDQ), and informant and self-reported behaviour (see Table 1 for more details on this recommendation).

Corroborated history from a reliable informant is essential (e.g., caregivers, spouses, children, relatives, close friends). For patients with negative corroborative history, reassurance should be provided, and a follow-up should be offered if the patient or informant sources note deterioration in the future in any of the domains of cognition, function, or behaviour. For patients with a positive corroborative history, a referral to a primary or specialty care

## Dementia Journey Transition Points: Family Doctor




Figure 2. Dementia journey transition points: family doctor (adapted from figure developed in collaboration with the Alzheimer Society of Canada).

memory clinic and further investigation with laboratory testing, neuroimaging, and detailed neuropsychiatric testing might be considered. All patients with SCD should be provided with information on World Health Organization recommendations for the prevention of dementia (World Health Organization, 2019).

**Use of neuroimaging for the diagnosis and follow-up of dementia.** The CCCDTD5 recommends the use of anatomical neuroimaging for most situations (see Table 1 for specific situations needing imaging tests). An MRI is recommended in most situations over CT because of its higher sensitivity for vascular lesions as well as for some subtypes of dementia and rarer conditions (favour 3t MRI over 1.5t MRI when available and non-contraindicated).

### Deprescribing in dementia

**Aspirin.** Without a history of stroke or brain infarcts and in the absence of well-established indications (e.g., history of coronary artery disease), acetylsalicylic acid (Aspirin) is not recommended for patients with MCI or dementia, even if there is imaging evidence of covert white matter lesions of presumed vascular origin.

**Cognitive enhancers.** The CCCDTD5 builds on the recommendations of the CCCDTD4, which recommended that cholinesterase inhibitors (ChEIs) be considered in most persons with Alzheimer’s disease (mild, moderate, and severe) as well as those with Alzheimer’s disease with a component of cerebrovascular disease (mixed Alzheimer’s disease – vascular dementia being

most common) and Parkinson’s disease dementia (Moore, Paterson, Lee, Vedel, & Bergman, 2014).


The CCCDTD5 recommends that, in some specific cases, a trial of ChEIs can be considered for the treatment of vascular dementia. Furthermore, the CCCDTD5 offers complementary recommendations on deprescribing ChEIs where appropriate for individuals taking a ChEI for Alzheimer’s disease, Parkinson’s disease dementia, Lewy body dementia, or vascular dementia for > 12 months. See Table 1 for specific situations in which deprescribing should be considered.

If the patient has been prescribed a ChEI or memantine for MCI or for a type of dementia other than Alzheimer’s disease, Parkinson’s disease dementia, Lewy body dementia, and vascular dementia, it should be discontinued.

Deprescribing of ChEIs or memantine should occur gradually and treatment reinitiated if the individual shows clinically meaningful worsening of cognition, functioning, neuropsychiatric symptoms, or global assessment that appears to be related to cessation of therapy. Individuals who have had a clinically meaningful reduction in neuropsychiatric symptoms (e.g., psychosis) with cognitive enhancers should continue to be treated with the cognitive enhancer, even if there is evidence of cognitive and functional decline.

All deprescribing decisions of these medications should take into consideration the patient’s preference and include consultation with a family member or substitute decision maker for persons who cannot consent.

## Dementia Journey Transition Points: Person with Dementia



\* Not everyone will get diagnosed, and a diagnosis does not always happen at the beginning of the journey. Throughout the journey the person may experience a change in their sense of identity, personal relationships and ongoing readjustment to a new normal. Individual experiences are unique and may not appear as linear transition points.

**Figure 3.** Dementia journey transition points: person living with dementia (developed in collaboration with the Alzheimer Society of Canada).

### Psychosocial and non-pharmacological interventions

**Exercise.** Group or individual physical exercise for PLWD is recommended, but there is no specific recommendation on the duration or intensity. This should be discussed and planned based on individual circumstances and preferences.

**Cognitive stimulation therapy.** Cognitive stimulation therapy, such as engaging in hobbies or volunteering, is the most widely used non-pharmacological intervention for dementia (Piras *et al.*, 2017) and may stimulate information processing in PLWD (Clarkson *et al.*, 2017). Based on implicit learning, it stimulates language and executive functioning, focusing on orientation, reminiscence, new ideas, thoughts, and associations (Piras *et al.*, 2017). Group cognitive stimulation therapy is recommended for persons living with mild to moderate dementia. Primary care clinicians should have information for patients on these services where available.

**Psychoeducational interventions.** Psychoeducational interventions provide information to the caregivers on the disease and adequate management of dementia, helping them develop coping skills and strategies (Ponce *et al.*, 2011). Psychosocial and psychoeducational interventions for caregivers of PLWD include education, counseling, information regarding services, enhancing carer skills to provide care, problem-solving, and strategy development. Primary care

clinicians should have information for patients on these services when available.

**Case management.** Case management is an intervention that may improve the quality of care that patients and caregivers receive by managing and coordinating services (Khanassov, Vedel, & Pluye, 2014). Case management uses a collaborative process for managing dementia cases (including the assessment, planning, care coordination, and advocacy for options and services to meet the patients' and caregivers' needs) (Khanassov *et al.*, 2014). Where available, implementation of a case management approach should be considered in primary care practice for PLWD.

**Dementia-friendly communities and organizations.** Dementia-friendly organizations aim to preserve the safety and well-being of PLWD (Hebert & Scales, 2019). In health care, a dementia-friendly organization is aware of the impact dementia has on a person's ability to engage with services and manage their health. Dementia-friendly organizations implement activities and changes to promote the inclusion of PLWD and caregivers in decisions and discussions to improve outcomes (Vedel *et al.*, 2020). Primary care practices should also consider advocating for and becoming a dementia-friendly organization.



**Table 2.** List of medication with anticholinergic properties to be avoided based on the American Geriatrics Society Beer's Criteria for potentially inappropriate medication use in the older adults

Medication Type	Medication Name(s)
Antiarrhythmic	Disopyramide
Antidepressants	Amitriptyline Amoxapine Clomipramine Desipramine Doxepin (> 6 mg) Imipramine Nortriptyline Paroxetine Protriptyline Trimipramine
Antiemetics	Prochlorperazine Promethazine
Antihistamines (first generation)	Brompheniramine Carbonoxamine Chlorpheniramine Clemastine Cyproheptadine Dexbrompheniramine Dexchlorpheniramine Dimhydrinate Diphenhydramine (oral) Doxylamine Hydroxyzine Meclizine
Antimuscarinics (urinary incontinence)	Darifenacin Fesoterodone Flavoxate Oxybutynin Solifenacin Tolterodine Trospium
Antiparkinsonian agents	Benzotropine Trihexyphenidyl
Antipsychotics	Chlorpromazine Clozapine Loxapine Olanzapine Perphenazine Thioridazine Trifluoperazine
Antispasmodics	Atropine Belladonna alkaloids Scopolamine
Skeletal muscle relaxants	Cyclobenzaprine Orphenadrine

Modified from the American Geriatrics Society 2019 Updated AGS Beers Criteria\* for Potentially Inappropriate Medication Use in Older Adults. *Journal of the American Geriatrics Society*. 2019;67(4):674–694.

### Additional Resources

Below, we compiled a small list of selected available resources that could potentially aid primary care clinicians in their practice with dementia patients. These resources are not present on the CCCDTD5 list of recommendations and are in the present article to provide tailored information for primary care providers. Figures 2 and 3 were developed in collaboration with the Alzheimer Society of Canada. These figures include two dementia journeys, one for the patient and one for the health and social care provider.

As seen above, the care of PLWD requires a comprehensive network of professionals. We recommend consulting the Interdisciplinary Primary Care Pathways (Interdisciplinary Clinical Process – Family Medicine Group (FMG), 2020a; Interdisciplinary Clinical Process – Family Medicine Group (FMG), 2020b), divided into two components: diagnosis and follow-up. Although it was developed for the context of primary care groups in the province of Quebec, coupled with the Dementia Journeys for health and social care providers and PLWD (see Figures 2 and 3), it can be a good resource for understanding and getting an overall view of the importance of collaborating closely with a multidisciplinary team and providing examples of when other professionals can be involved in the care of PLWD.

The Forward with Dementia website (available in French and English: [www.forward-avancer.ca](http://www.forward-avancer.ca) and [www.forwardwithdementia.ca](http://www.forwardwithdementia.ca)) is a resource created by an international team effort and with the input of PLWD, care partners, and health and social care providers. To provide a message of hope and guidance for PLWD and their care partners after the diagnosis of dementia, it offers tailored information regarding several topics, including nutrition, exercise, and social engagement activities. There are also resources for health and social care providers.

Although the CCCDTD5 recommends exercise both as prevention and as part of the treatment of dementia, it does not provide enough evidence to support one type of exercise above others. However, resources are available for the general population of ages 65 years and older for recommending exercise. For instance, the guidelines developed by the Canadian 24-hour movement, tailored for adults ages 65 years and older (The Canadian Society for Exercise Physiology, 2021), as well as the resources of Western University in Canada to improve balance (Canadian Centre for Activity and Aging – Western University, 2022) can be a good complement: <https://csepguidelines.ca/guidelines/adults-65/> and [https://www.uwo.ca/ccaa/programs/videos/balance\\_flexibility.html](https://www.uwo.ca/ccaa/programs/videos/balance_flexibility.html).

**Table 3.** Risk factors for, and medical conditions associated with, neurocognitive disorders

Risk Factors for Neurocognitive Disorders	Medical Conditions Associated with Neurocognitive Disorders
History of stroke or transient ischemic attack (TIA)	Late onset of depression, psychosis, anxiety, or mania
Lifetime history of major depressive disorder	Untreated sleep apnea
Unstable metabolic or cardiovascular morbidity	Recent episode of delirium
Recent head injury	Parkinson's disease

**Table 4.** Psychometric screening tools for assessing cognitive function

Rapid Tools	Comprehensive Tools
Memory Impairment Screen (MIS)+ clock drawing test (CDT)	Modified Mini-Mental State (3MS) examination
the Mini-Cog	Mini-Mental State Examination (MMSE)*
AD8	Rowland Universal Dementia Assessment Scale (RUDAS)
Four-item version of the MoCA (Clock-drawing, Tap-at-letter-A, Orientation, and Delayed-recall)	MoCA <sup>†</sup>
GP Assessment of Cognition (GPCOG)	

\*MMSE remains the most widely used instrument, with high sensitivity and specificity for separating moderate dementia from normal cognition and is recommended in many countries.

<sup>†</sup>The MoCA is more sensitive to MCI than the MMSE, and its use is recommended when mild cognitive impairment is suspected or in cases where there is suspicion of cognitive impairment or concern about the patient's cognitive status, and the MMSE score is in the "normal" range (24+ out of 30).

**Table 5.** Potential symptoms of neurocognitive decline in older individuals

Potential Symptoms of Neurocognitive Decline in Older Individuals
Difficulty remembering or following instructions or taking medications
Decline in instrumental activities of living
New onset of later-life behavioural changes, including new depression or anxiety
Missing or arriving late to appointments, confusing day of the appointment
Decrease in self-care
Victimized by financial scams

## Discussion

The present article tailors the results of the CCCDTD5 recommendations for primary care providers, which are crucial for the management and treatment of dementia in Canada. Primary care practitioners need evidence-based relevant recommendations to guide the diagnosis and management of dementia in family practice. In addition, with the help of knowledge translation experts, we created visual representations that can help primary care providers visualize when, in the journey of dementia, they can apply these recommendations. The new recommendations in the CCCDTD5 can help guide screening, diagnosis, and pharmacological and non-pharmacological interventions for PLWD and their caregivers in primary care settings.

Future guidelines should focus on emerging diagnostic, therapeutic interventions, and better long-term management supports. For example, while the CCCDTD5 could not recommend specific exercises or cognitive training, there is much ongoing research in this field, and we expect many advances in the coming years to guide better dementia care practices (Livingston *et al.*, 2017). It is critical that primary care practitioners remain up-to-date and skilled in dementia care to better meet the needs of the aging Canadian population we serve. Future iterations of this conference (e.g., CCCDTD6) could cover additional topics essential for dementia care in primary and specialized care, such as medical assistance in dying (including the ethical and human rights implications and considerations), virtual dementia care and its appropriateness for this population, driving assessment for persons living with dementia, and awareness and respect of human rights for dementia patients with particular emphasis on patients with severe cognitive impairment at the time of shortage of medical care (i.e., during the SARS-CoV-2 [COVID-19] pandemic). In addition, sex and gender were not considered during the CCCDTD5. Future

iterations should consider these to better tailor the recommendations to specific populations. Furthermore, additional efforts in knowledge translation should continue to be made for future dementia guidelines to answer to the needs of health care providers in primary care in Canada.

## Conclusion

The present article tailored the recommendations from the CCCDTD5 for primary care in a more practical manner to consult. The discussed knowledge translation strategy helps these important recommendations reach knowledge users. The development of recommendations for the ongoing management of dementia is an iterative process as new evidence on interventions for dementia is published. The present article's recommendations are not only focused on treating dementia after the diagnosis. Primary care providers can start action plans to reduce the risk of dementia in the general population and those at risk. It is not recommended to screen asymptomatic patients. However, special attention should be provided to those with symptoms, including patients complaining of subjective cognitive decline. In addition, medications for dementia should be approached based on the patient's characteristics, as not all persons with dementia should be prescribed medications such as aspirin or cholinesterase inhibitors. These recommendations on risk reduction, screening and diagnosis, deprescription of dementia medications, and non-pharmacological interventions for dementia are important in the primary care setting as it is the entry point for PLWD into the health system.

**Acknowledgements.** We want to thank all members of the CCCDTD5's panel of experts. We would also like to thank Juliette Champoux-Pellegrin, Administrative Coordinator for ROSA Team at the Lady Davis Institute for Medical Research, Jewish General Hospital in Montreal, who helped with the conception of Figure 1 and the grammar revision and formatting of the article. We would like to thank the Alzheimer Society of Canada for collaborating with us in the development of Figures 2 and 3 on the dementia journey transition points.

**Funding.** The work of Laura Rojas-Rozo and Juliette Champoux-Pellegrin was supported by the Canadian Consortium on Neurodegeneration in Aging (CCNA), which is supported by a grant from the Canadian Institutes of Health Research with funding from several partners (grant number CCNA137794).

The CCCDTD5 meeting was supported financially by the CCNA, the Réseau des cliniques mémoire du Québec, the Réseau Québécois de Recherche sur le Vieillessement.

**Competing interest.** The authors report no conflicts of interest.

## References

- Alzheimer Disease International. (2020). Alzheimer Disease International. The Global Voice on Dementia: About dementia. Retrieved October 15, 2021, from <https://www.alz.co.uk/about-dementia>.
- American Psychiatric Association. (2013). *Diagnostic and statistical manual of mental disorders (DSM-5®)*. Arlington, VA: American Psychiatric Association Publishing.
- Arsenault-Lapierre, G., Henein, M., Rojas-Rozo, L., Bergman, H., Couturier, Y., & Vedel, I. (2021). Primary care clinicians' attitudes, knowledge and practice toward dementia: They are willing and need training! *Canadian Family Physician Journal*, *67*(10), 731–735. <https://doi.org/10.46747/cfp.6710731>
- Bacsu, J., Mateen, F. J., Johnson, S., Viger, M. D., & Hackett, P. (2020). Improving dementia care among family physicians: From stigma to evidence-informed knowledge. *Canadian Geriatrics Journal*, *23*(4), 340–343. <https://doi.org/10.5770/cgj.23.426>
- Black, B. S., Johnston, D., Rabins, P. V., Morrison, A., Lyketsos, C., & Samus, Q. M. (2013). Unmet needs of community-residing persons with dementia and their informal caregivers: Findings from the maximizing independence at home study. *Journal of the American Geriatrics Society*, *61*(12), 2087–2095. <https://doi.org/10.1111/jgs.12549>
- Brouwers, M. C., Kho, M. E., Browman, G. P., Burgers, J. S., Cluzeau, F., Feder, G., et al. (2010). AGREE II: Advancing guideline development, reporting and evaluation in health care. *CMAJ*, *182*(18), E839–E842.
- Canadian Academy of Health Science. (2019). Improving the quality of life and care of persons living with dementia and their caregivers. Retrieved September 20, 2022, from <https://www.caahs-acss.ca/wp-content/uploads/2019/01/Report.pdf>.
- Canadian Centre for Activity and Aging - Western University. (2022). Active at home videos: Balance practice. Retrieved September 20, 2022, from [https://www.uwo.ca/ccaa/programs/videos/balance\\_flexibility.html](https://www.uwo.ca/ccaa/programs/videos/balance_flexibility.html).
- Canadian Institute for Health Information. (2022). Family doctor preparedness. Retrieved September 20, 2022, from <https://www.cihi.ca/en/dementia-in-canada/spotlight-on-dementia-issues/family-doctor-preparedness>.
- Carr, D. B., & Ott, B. R. (2010). The older adult driver with cognitive impairment: It's a very frustrating life. *JAMA*, *303*(16), 1632–1641. <https://doi.org/10.1001/jama.2010.481>
- CCCDTD3. (2007). 3<sup>rd</sup> Canadian Consensus Conference on Diagnosis and Treatment of Dementia: 146 Approved Recommendations. Retrieved October 15, 2021, from <https://sinaigeriatrics.ca/wp-content/uploads/2017/05/2007-CCCDFinal.pdf>.
- Clarkson, P., Hughes, J., Xie, C., Larbey, M., Roe, B., Giebel, C. M., et al. (2017). Overview of systematic reviews: Effective home support in dementia care, components and impacts-Stage 1, psychosocial interventions for dementia. *Journal of Advanced Nursing*, *73*(12), 2845–2863. <https://doi.org/10.1111/jan.13362>
- Gauthier, S., Chertkow, H., Theriault, J., Chayer, C., Ménard, M.-C., Lacombe, G., et al. (2020). CCCDTD5: Research diagnostic criteria for Alzheimer's disease. *Alzheimer's & Dementia: Translational Research & Clinical Interventions*, *6*(1), e12036. <https://doi.org/10.1002/trc2.12036>
- Geddes, M. R., O'Connell, M. E., Fisk, J. D., Gauthier, S., Camicioli, R., Ismail, Z., et al. (2020). Remote cognitive and behavioral assessment: Report of the Alzheimer society of Canada task force on dementia care best practices for COVID-19. *Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring*, *12*(1), e12111. <https://doi.org/10.1002/dad2.12111>
- Gupta, S., Rai, N., Bhattacharya, O., Cheng, A. Y. Y., Connelly, K. A., Boulet, L.-P., et al. (2016). Optimizing the language and format of guidelines to improve guideline uptake. *Canadian Medical Association Journal*, *188*(14), E362–E368. <https://doi.org/10.1503/cmaj.151102>
- Hebert, C. A., & Scales, K. (2019). Dementia friendly initiatives: A state of the science review. *Dementia*, *18*(5), 1858–1895. <https://doi.org/10.1177/1471301217731433>
- Hogan, D. B., Borrie, M., Basran, J. F. S., Chung, A. M., Jarrett, P. G., Morais, J. A., et al. (2012). Specialist physicians in geriatrics-report of the Canadian geriatrics society physician resource work group. *Canadian Geriatrics Journal: CGJ*, *15*(3), 68–79. <https://doi.org/10.5770/cgj.15.41>
- Honda, Y., Meguro, K., Meguro, M., & Akanuma, K. (2013). Social withdrawal of persons with vascular dementia associated with disturbance of basic daily activities, apathy, and impaired social judgment. *Care Management Journals*, *14*(2), 108–113. <https://doi.org/10.1891/1521-0987.14.2.108>
- Hsu, J. W., & Willis, R. (2013). Dementia risk and financial decision making by older households: The impact of information. *Journal of Human Capital*, *2013*, 45–45. <https://doi.org/10.2139/ssrn.2339225>
- Interdisciplinary Clinical Process – Family Medicine Group (FMG). (2020a). Outreach services mild or major neurocognitive disorders (mNCD or MNCD) - diagnosis component (1). Retrieved September 20, 2022, from [https://www.mcgill.ca/familymed/files/familymed/interdisciplinary\\_clinical\\_process\\_diagnostic.pdf](https://www.mcgill.ca/familymed/files/familymed/interdisciplinary_clinical_process_diagnostic.pdf).
- Interdisciplinary Clinical Process – Family Medicine Group (FMG). (2020b). Outreach services mild or major neurocognitive disorders (mNCD or MNCD) - follow-up component (2). Retrieved September 20, 2022, from [https://www.mcgill.ca/familymed/files/familymed/interdisciplinary\\_clinical\\_process\\_follow-up.pdf](https://www.mcgill.ca/familymed/files/familymed/interdisciplinary_clinical_process_follow-up.pdf).
- Ismail, Z., Black, S. E., Camicioli, R., Chertkow, H., Herrmann, N., Laforce Jr, R., et al. (2020). Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia. *Alzheimer's & Dementia*, *16*(8), 1182–1195. <https://doi.org/10.1002/alz.12105>
- Khanassov, V., Rojas-Rozo, L., Sourial, R., Yang, X., & Vedel, I. (2021). Needs of patients with dementia and their caregivers in primary care: Lessons learned from the Alzheimer plan of Quebec. *BMC Family Practice*, *22*(1), 186. <https://doi.org/10.1186/s12875-021-01528-3>
- Khanassov, V., Vedel, I., & Pluye, P. (2014). Case management for dementia in primary health care: A systematic mixed studies review based on the diffusion of innovation model. *Clinical Interventions in Aging*, *9*, 915. <https://doi.org/10.2147/CIA.S64723>
- Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S. G., Huntley, J., Ames, D., et al. (2017). Dementia prevention, intervention, and care. *Lancet*, *390*(10113), 2673–2734. [https://doi.org/10.1016/s0140-6736\(17\)31363-6](https://doi.org/10.1016/s0140-6736(17)31363-6)
- Molnar, F. J., Benjamin, S., Hawkins, S. A., Briscoe, M., & Ehsan, S. (2020). One size does not fit all: Choosing practical cognitive screening tools for your practice. *Journal of the American Geriatrics Society*, *68*(10), 2207–2213. <https://doi.org/10.1111/jgs.16713>
- Moore, A., Patterson, C., Lee, L., Vedel, I., & Bergman, H. (2014). Fourth Canadian consensus conference on the diagnosis and treatment of Dementia: Recommendations for family physicians. *Canadian Family Physician*, *60*(5), 433–438.
- Piras, F., Carbone, E., Faggian, S., Salvalaio, E., Gardini, S., & Borella, E. (2017). Efficacy of cognitive stimulation therapy for older adults with vascular dementia. *Dement Neuropsychol*, *11*(4), 434–441. <https://doi.org/10.1590/1980-57642016dn11-040014>
- Ponce, C. C., Ordonez, T. N., Lima-Silva, T. B., Dos Santos, G. D., de Fátima Viola, L., Nunes, P. V., et al. (2011). Effects of a psychoeducational intervention in family caregivers of people with Alzheimer's disease. *Dement Neuropsychol*, *5*(3), 226–237. <https://doi.org/10.1590/S1980-57642011DN05030011>
- Stuart, A. N., & Nitrini, R. (2016). Subjective cognitive decline: The first clinical manifestation of Alzheimer's disease? *Dement Neuropsychol*, *10*(3), 170–177. <https://doi.org/10.1590/s1980-5764-2016dn1003002>
- The American Geriatrics Society Beers Criteria Update Expert Panel (2019). American geriatrics society 2019 updated AGS beers criteria\* for potentially inappropriate medication use in older adults. *Journal of the American Geriatrics Society*, *67*(4), 674–694. <https://doi.org/10.1111/jgs.15767>
- The Canadian Society for Exercise Physiology. (2021). Canadian 24-hour movement guidelines for adults aged 65 years and older: An integration of physical activity, sedentary behaviour, and sleep. Canada. Retrieved September 20, 2022, from <https://csepguidelines.ca/guidelines/adults-65/>.
- The Common Wealth Fund. (2015). 2015 commonwealth fund international survey of primary care physicians in 10 Nations. Retrieved September 20, 2022, from <https://www.commonwealthfund.org/publications/surveys/2015/dec/2015-commonwealth-fund-international-survey-primary-care-physicians>

- Vedel, I., Sheets, D., McAiney, C., Clare, L., Brodaty, H., Mann, J., et al. (2020). CCCDTD5: Individual and community based psychosocial and other non-pharmacological interventions to support persons living with dementia and caregivers. *Alzheimer's & Dementia: Translational Research & Clinical Interventions*, **6**, e12086. <https://doi.org/10.1002/trc2.12086>
- World Health Organization. (2012). Dementia: A public health priority. Retrieved October 15, 2021, from <https://extranet.who.int/agefriendlyworld/wp-content/uploads/2014/06/WHO-Dementia-English.pdf>.
- World Health Organization. (2019). Risk reduction of cognitive decline and dementia: WHO guidelines.